In short bowel syndrome, octreotide injections are most beneficial when there is which condition?

• A. intact colon
• B. short bowel secondary to mesenteric ischemia
• C. short bowel secondary to inflammatory bowel disease
• D. refractory diarrhea not controlled with standard antidiarrheal agents

Answer: (D)

In short bowel syndrome, the main goal is to reduce stool output to improve nutrient absorption and hydration. Octreotide, a somatostatin analog, lowers gastrointestinal secretions and slows intestinal transit, which helps decrease diarrhea and allows more time for remaining bowel to absorb nutrients. The situation where octreotide is most beneficial is when diarrhea remains high-volume despite standard antidiarrheal measures and dietary adjustments. In this refractory state, octreotide can substantially cut stool volume, improve fluid balance, and support nutritional rehabilitation, sometimes enabling weaning from parenteral nutrition. The presence or absence of a colon, or the underlying cause of the short bowel (such as mesenteric ischemia or inflammatory bowel disease), does not by itself predict a better response; the key factor is that diarrhea is not controlled with conventional therapies.